High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.

Background: Low bone mineral density (BMD) is an emerging metabolic condition in HIV-infected patients; however, data on progression of this disease are scarce.

Methods: We studied 671 patients with at least one dual-energy X-ray absorptiometry scan (391 of them ≥2 scans) to determine the prevalence and progression of BMD and establish related factors. Linear regression and logistic polytomic regression were used for the cross-sectional study and mixed effects and generalized estimating equations were used for the longitudinal study.

Results: Osteopenia and osteoporosis were diagnosed in 47.5 and 23%, respectively. Progression to bone demineralization was observed in 28% of the patients over a median of 2.5 years (12.5% progressed to osteopenia and 15.6% to osteoporosis). In the 105 patients with at least 5 years of follow-up, progression was 47% (18% to osteopenia; 29% to osteoporosis). Factors associated with bone loss and progression were age [odds ratio (OR) 1.07; 95% confidence interval (CI) 1.05-1.08; P 0.0001], male sex (OR 2.23; 95% CI 1.77-2.8; P 0.0001), low body mass index (OR 1.14; 95% CI 1.11-1.17; P 0.0001), time on protease inhibitor (OR 1.18; 95% CI 1.12-1.24; P 0.0001), time on tenofovir (OR 1.08; 95% CI 1.03-1.14; P 0.0019), and current use of protease inhibitors (OR 1.64; 95% CI 1.35-2.04; P 0.0001).

Conclusion: Osteopenia and osteoporosis were diagnosed in 47.5 and 23%, respectively. Progression to bone demineralization was observed in 28% of the patients over a median of 2.5 years (12.5% progressed to osteopenia and 15.6% to osteoporosis). In the 105 patients with at least 5 years of follow-up, progression was 47% (18% to osteopenia; 29% to osteoporosis). Factors associated with bone loss and progression were age [odds ratio (OR) 1.07; 95% confidence interval (CI) 1.05-1.08; P 0.0001], male sex (OR 2.23; 95% CI 1.77-2.8; P 0.0001), low body mass index (OR 1.14; 95% CI 1.11-1.17; P 0.0001), time on protease inhibitor (OR 1.18; 95% CI 1.12-1.24; P 0.0001), time on tenofovir (OR 1.08; 95% CI 1.03-1.14; P 0.0019), and current use of protease inhibitors (OR 1.64; 95% CI 1.35-2.04; P 0.0001).